885270-77-9

Usage

Uses

Used in Pharmaceutical Industry:
(2-AMINO-5-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as a building block for the synthesis of biologically active compounds, contributing to the development of new pharmaceuticals due to its chemical properties that allow for the creation of diverse medicinal agents.
Used in Research and Development:
In the realm of research and development, (2-AMINO-5-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER serves as a crucial component in the production of innovative drugs, underpinning experimental procedures aimed at discovering and refining new therapeutic agents.
Used in Agricultural Applications:
Though not fully detailed in the provided materials, (2-AMINO-5-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER may have potential uses in agriculture, possibly as a component in the development of agrochemicals or as a tool in agricultural research to enhance crop protection or yield.
Used as an Intermediate in Chemical Production:
(2-AMINO-5-METHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER also functions as an intermediate in the synthesis of other chemicals, indicating its versatility in various chemical processes and the potential for its use in a wide array of industrial applications.

Upstream product

• 578-46-1 5-methyl-2-nitroaniline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 496-72-0 4-methyl-1,2-diaminobenzene 
• 827-32-7 4-bromo-5-methyl-2-nitrophenylamine 

Downstream Products

• 1609929-53-4 1-acetyl-N-cyclohexyl-7-methyl-3-phenyl-1,4-dihydroquinoxaline-2-carboxamide 

Relevant academic research and scientific papers

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors

A series of 2-aminopyrimidine derivatives were designed and synthesized as highly selective FGFR4 inhibitors. One of the most promising compounds 2n tightly bound FGFR4 with a Kd value of 3.3 nM and potently inhibited its enzymatic activity with an IC50 value of 2.6 nM, but completely spared FGFR1/2/3. The compound selectively suppressed proliferation of breast cancer cells harboring dysregulated FGFR4 signaling with an IC50 value of 0.38 μM. Furthermore, 2n exhibited extraordinary target specificity in a Kinome-wide screen against 468 kinases, with S(35) and S(10) selectivity scores of 0.01 and 0.007 at 1.0 μM, respectively.

Discovery of a Selective Aurora A Kinase Inhibitor by Virtual Screening

Here we report the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential anticancer target. We used the atom category extended ligand overlap score (xLOS), a 3D ligand-based virtual screening method recently developed in our group, to select 437 shape and pharmacophore analogs of reference kinase inhibitors. Biochemical screening uncovered two inhibitor series with scaffolds unprecedented among kinase inhibitors. One of them was successfully optimized by structure-based design to a potent Aurora A inhibitor (IC50 = 2 nM) with very high kinome selectivity for Aurora kinases. This inhibitor locks Aurora A in an inactive conformation and disrupts binding to its activator protein TPX2, which impairs Aurora A localization at the mitotic spindle and induces cell division defects. This phenotype can be rescued by inhibitor-resistant Aurora A mutants. The inhibitor furthermore does not induce Aurora B specific effects in cells.

Histone deacetylase inhibitors based on derivatives of tricyclic polyhydroacridine and analogs possessing fused saturated five- and seven-membered rings

The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or chemoprevention of cancer hematological malignancy, prolifera

Guanidine hydrochloride as an organocatalyst for N-Boc protection of amino groups

A simple and efficient method for the chemoselective N-Boc protection of the amine moiety in a variety of compounds is described using di-tert-butyl dicarbonate and guanidine hydrochloride as an organocatalyst in ethanol at 35-40°C. Selective mono-N-Boc protection of diamines and chemoselective protection of hydroxylamines without formation of any side products is achieved. Amino acids and peptides are N-Boc protected efficiently in excellent yields under convenient reaction conditions.

MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176

Compounds of Formula 1, or pharmaceutically acceptable salts thereof: wherein X, R1, R2, R3, R4, R5, n, m, and p are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.